Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.
Overview
As the global healthcare landscape shifts toward weight-loss treatments and chronic care, investors are weighing two giants. Should you invest in Novo Nordisk A/S (NYSE:NVO) or Pfizer Inc.(NYSE:PFE) today?
Novo Nordisk A/S has built a dominant position in the diabetes market, while Pfizer offers a broad range of vaccines and medicines. They are now competing more directly as Pfizer expands into metabolic health. This comparison looks at their financials, risks, and valuations to determine which stock is the better choice for your portfolio.
Details
Novo Nordisk A/S focuses on serious chronic diseases, specifically diabetes and obesity. It operates a global business, marketing products in roughly 170 countries with a workforce of nearly 70,000 employees. The company maintains a specialized focus that distinguishes it from more diversified players among healthcare stocks. It does not report any single customer accounting for more than 10% of total revenue.
Source
Originally published at www.fool.com.